(Q36981731)

17 August 2017

1 reference

title

Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues (English)

1 reference

17 August 2017

L M Aledort

1

1 reference

17 August 2017

publication date

22 October 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

14

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

39-43

1 reference

Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Immune tolerance therapy for haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Inhibitor challenges in the paediatric setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

A retrospective postlicensure survey of FEIBA efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Treatment of acquired haemophilia with factor eight inhibitor bypassing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Long‐term FEIBA prophylaxis does not prevent progression of existing joint disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Thromboembolic adverse events after use of recombinant human coagulation factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity--a rebuttal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Inhibitors: resolving diagnostic and therapeutic dilemmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

21 January 2018

FEIBA: mode of action

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

FEIBA safety profile in multiple modes of clinical and home-therapy application

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01594.X

10.1111/J.1365-2516.2007.01594.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference